Baxter International receives approval for FEIBA.
M2 EQUITYBITES-December 23, 2013-Baxter International receives approval for FEIBA
(C)2013 M2 COMMUNICATIONS http://www.m2.com
It was reported on Friday that Baxter International, a United States-based healthcare company, has received approval for its FEIBA (Anti-Inhibitor Coagulant Complex) from the US Food and Drug Administration.
The product is reportedly the first and only FDA-approved treatment for routine prophylaxis to prevent or decrease the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.
The approval is based on data from a Phase III trial known as FEIBA PROOF, under which treatment with a FEIBA prophylactic regimen indicated a 72% reduction in median annual bleed rate against treatment with an on-demand regimen.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Dec 23, 2013|
|Previous Article:||NuStar's board elects Tom Shoaf as successor to retiring CFO Steve Blank.|
|Next Article:||Orion signs license agreement with Janssen.|